Evidence map›Paper›PMID 41543764›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2026

Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook.

Kurt A Jellinger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kurt A JellingerInstitute of Clinical Neurobiology, Alberichgasse 5/13, Vienna, A-1150, Austria. kurt.jellinger@univie.ac.at.ORCID http://orcid.org/0000-0002-9641-7649

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropsychiatric symptoms such as depression and apathy are frequently reported in all subgroups of frontotemporal dementia (FTD) or frontotemporal lobe degeneration (FTLD) and represent a substantial burden for both patients and caregivers. Both symptoms are most common in its behavioral variant (bvFTD) with a prevalence of up to 90%. Their severity is particularly high in bvFTD and the semantic variant of primary progressive aphasia (svPPA). Due to its clinical heterogeneity, bvFTD can mimic depression, especially in its initial stages, making their differentiation a major clinical challenge. The relationship between depression and the even more often presenting apathy is unclear, although they frequently co-occur and overlap. Depression in FTD is associated with atrophy in the left prefrontal/orbitofrontal cortex, supramarginal and postcentral gyrus, connected with dysfunction of neuronal networks involved in the pathogenesis of major depressive disorder and frontotemporal hypometabolism. Apathy, a core behavioral symptom in bvFTD, is associated with similar cortical atrophies on the right side and disordered networks between prefronto-striatal and other circuits. Since currently no curative treatment for FTD is available, the management of the basic disease and associated depression and apathy is mostly symptomatic. Most pharmacological interventions are without convincing effect; for depression, electroconvulsive therapy is a beneficial option, as is transcranial magnetic stimulation for apathy, but there is an impetus to develop general guidelines for the diagnosis and effective treatment of FTD and associated depression and apathy.

Indexed as

ApathyDepressionFrontotemporal DementiaHumansApathyDepressionFDG-PETFrontotemporal dementiaFrontotemporal lobe degenerationNetwork mappingTreatment options

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.